Publication: Potential of recombinant 2-Cys peroxiredoxin protein as a vaccine for Fasciola gigantica infection
Issued Date
2018-11-01
Resource Type
ISSN
10902449
00144894
00144894
Other identifier(s)
2-s2.0-85054808400
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Experimental Parasitology. Vol.194, (2018), 16-23
Suggested Citation
Kant Sangpairoj, Somjai Apisawetakan, Narin Changklungmoa, Pornanan Kueakhai, Pannigan Chaichanasak, Prasert Sobhon, Kulathida Chaithirayanon Potential of recombinant 2-Cys peroxiredoxin protein as a vaccine for Fasciola gigantica infection. Experimental Parasitology. Vol.194, (2018), 16-23. doi:10.1016/j.exppara.2018.09.005 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/45948
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Potential of recombinant 2-Cys peroxiredoxin protein as a vaccine for Fasciola gigantica infection
Abstract
© 2018 Helminth 2-cys peroxiredoxin (Prx) is a major antioxidant enzyme that protects parasites against hydrogen peroxide-generating oxidative stress from the hosts’ immune responses. This enzyme has been found in all stages of the tropical liver fluke, Fasciola gigantica. To investigate the potential of the recombinant F. gigantica Prx-2 (rFgPrx-2) as a vaccine candidate, vaccine trials in mice were carried out. In this study, the ICR mice were immunized with rFgPrx-2 combined with Freund's adjuvant and infected with F. gigantica metacercariae. The vaccine efficacy was estimated by quantitate fluke recovery, antibody levels and liver function. The protection by rFgPrx-2 against F. gigantica infection was achieved at 43–46% compared with adjuvant-infected and non-immunized-infected control groups, respectively. The vaccine elicited both Th1 and Th2 humoral immune responses with predominance of Th2 as indicated by the higher level of IgG1 in sera of immunized mice. However, the levels of liver damage markers, serum glutamate oxalic transaminase (SGOT) and serum glutamic pyruvate transaminase (SGPT) in rFgPrx-2 immunized group did not show significant difference in comparison with the controls. This study suggested that rFgPrx-2 may have a potential as a vaccine against tropical fasciolosis.